Share through
St. Jude Research Logo
About Us
Care & Treatment
Research
Training
Get Involved
Ways to Give
St. Jude Research
WHY ST. JUDE
Back
WHY ST. JUDE
Data and Visualization Tools
Shared Resources
Why St.Jude
Translation Innovation
Scientific Milestones
DEPARTMENTS & LABS
Back
DEPARTMENTS & LABS
Departments
View all departments
Labs
View all labs
Clinical Research
View all clinical researchers
CENTERS & INITIATIVES
Back
CENTERS & INITIATIVES
Comprehensive Cancer Center
Pediatric Translational Neuroscience Initiative
Blue Sky
St. Jude Research Collaboratives
Centers & Initiatives
Global Impact on Infectious Disease
Center of Excellence for Data-Driven Discovery
Center of Excellence for Innate Immunity and Inflammation
Center of Excellence for Pediatric Immuno-Oncology
CAREERS
Search
When autocomplete results are available use up and down arrows to review and enter to select. Touch device users, explore by touch or with swipe gestures.
Home
Why St. Jude
Shared resources & core facilities
Technology Licensing
Drugs
Drugs
AdamTS4 inhibitor for respiratory infection (SJ-20-0025)
Amylase or maltose to treat or prevent neurodegeneration (SJ-20-0009)
BET Bromodomain inhibitors (SJ-16-0032)
CDK2 PROTACS for Hearing Loss and Cancer (SJ-20-0021)
Chloroquine and chloroquine analogs (SJ-02-0008, SJ-05-0017)
Combination IFN and NEI Therapy for Cancer (SJ-21-0033)
Diagnosing and treating learning or mental disorders with SERCA2 protein and miRNAs (SJ-10-0003, SJ-12-0020)
Drug combination for treating cytokine storms of COVID-19 and other conditions (SJ-21-0008)
EZHIP(CXorf67)-PRC2 interaction and ependymoma (SJ-17-0030)
GNCK1a/CK1alpha degrading compounds (SJ-22-0028, SJ-21-0048)
Human G1 To S Phase Transition Protein 1 Homolog (GSPT1) Degrader (SJ-21-0001)
Hybrid compounds to treat gastrointestinal infections (SJ-14-0019/UTA 14-01)
Improving learning and treating neurological diseases (SJ-15-0009)
JAK PROTAC (SJ-19-0047)
MAGE-A11 inhibitor for cancer (SJ-20-0033)
New JAK PROTACs (SJ-21-0010)
Novel carboxylesterase inhibitors (SJ-02-0030)
PROTACs for GSPT1 and PXR (SJ-22-0029)
Preventing and treating hearing loss using CDK2 inhibitors (SJ-14-0028)
Proteolytic Targeting Chimeras (PROTACs) for Targeting LCK-driven Leukemia (SJ-21-0047)
SARM for Kennedy's disease (SJ-18-0012)
SPA70 is a potent antagonist of human pregnane X receptor (PXR antagonists) (SJ-16-0011)
Small molecule modulators of PanK (SJ-18-0046)
Small molecules that can be used for targeted protein degradation of GSPT1/IKZF1 (SJ-21-0045)
Specific retinoid receptor agonists and antagonists for cancer (SJ-14-0011)
Thalamic microRNA controls the late onset of schizophrenia (SJ-15-0035)
Therapeutic leads targeting influenza endonuclease (SJ-09-0041)
Transcription factors for cochlear hearing loss therapy (SJ-17-0016)
Treating cochlear hearing loss with p27Kip1/Atoh1 combinations (SJ-13-0019)
Use of Ulk1 modulators to treat thalassemia (SJ-18-0004)
Use of metabolic drugs to treat influenza infection (SJ-14-0040)
VIPR1 modulators for improving auditory capabilities (SJ-22-0023)
For more information
Contact the
Office of Technology Licensing
:
Phone: (901) 595-2342
Fax: (901) 595-3148
OTL Intellectual Properties Newsletters
More technologies
Antibodies for basic research
Biologics
Diagnostics
Drug discovery development tools
Other technologies
Vaccines
Contact Us
View all Shared Resources